CCRT was analyzed both as a continuous variable (per day) and as a categorical variable in 2 groups (Group 1 $\leq$ median, Group 2 $>$ median). Patients with a waiting time of more than 60 days were excluded.

Results The median waiting time was 14 days (0–60). There were differences between Group 1 and Group 2 in age and type of chemotherapy. However, no significant difference was found in the FIGO stage, cell type, or the number of cycles of chemotherapy received during CCRT. A longer waiting time was associated with poorer overall survival on the Kaplan-Meier curve (Group 1 vs. Group 2, $P = 0.042$). On multivariate analysis, intervals as either a continuous variable (HR; 1.023, 95% CI; 1.006–1.040, $P = 0.007$) or a categorical variable (HR; 1.513, 95% CI; 1.073–2.134, $P = 0.018$), FIGO stage, cell type, and the number of cycles of chemotherapy received during CCRT were significant independent prognostic factors for overall survival.

Patients were divided into two groups based on the median waiting time.

Conclusions A longer waiting time from pathological diagnosis to definitive CCRT was associated with worse overall survival. Our findings suggest that an effort to minimize waiting times should be made in cervical cancer patients who are candidates for CCRT.

IGCS20_1394

368 OVARIAN SERTOLI-LEYDIG TUMORS : EPIDEMIOLOGICAL AND PROGNOSTIC FEATURES

¹O Kaabia*, ¹O Ben Ahmed, ²T Yaacoubi, ¹M Bibi, ²M Mokni, ¹H Khairi. ¹Université de Sousse, Faculté de Médecine de Sousse, Hôpital Farhat Hached, Sousse, Tunisie, Tunisia; ²Université de Sousse, Faculté de Médecine de Sousse, Hôpital Farhat Hached, Department of Pathology, Sousse, Tunisie, Tunisia

10.1136/ijgc-2020-IGCS.318

Objectives Sertoli Leydig cell tumors (SLCT) belong to the group of sex cord-stromal tumors. SLCTs of the ovary are rare (less than 0.5% of all ovarian tumors). The aim of this study is to establish the epidemiological and prognostic features of such a rare tumor entity.

Methods We conducted a retrospective study over a 12 year period (2004–2015) in the Tunisian Central Cancer Registry. We collected all the pathology established cases of ovarian SLCT.

Results The incidence of ovarian SLCT was 1.5% of all the Ovarian, fallopian tube, and peritoneal cancers in our registry. The mean age at the diagnosis was 30 years [14 – 79] with a 2-peak distribution: 14 –30 years (46.15% of the patients) and 50 – 80 years. Endocrine symptoms were present in 76,92% of the patients (virilization: 38.46%). Testosterone serum levels were high in 33.33% of the patients. The pathological FIGO staging was IA in 15.38%, IC in 61.53%, and IIIC in 23.07%. A fertility-sparing surgery was performed in 46.15%. Adjuvant chemotherapy (bleomycin, etoposide, and Cisplatin) was delivered in 46.15%. The recurrence rate in the conservatively operated group was 16.67% and the overall progression rate was 47.46%. The overall survival at 5 years was 38%.

Conclusions Our results suggest that ovarian SLCT are rare but can occur at any age, even in menopausal women. The clinical features are essentially endocrine symptoms. In young women, fertility-sparing surgery is feasible but with a 16.67% recurrency rate and 38% 5- year overall survival.

IGCS20_1395

369 PHASE II TRIAL ON THE FEASIBILITY OF SINGLE DOSE INTRAOPERATIVE NORMOTHERMIC INTRAPERITONEAL CARBOPLATIN (NIPEC) IN ADVANCED EPITHELIAL OVARIAN CANCER FOLLOWING OPTIMAL CYTOREDUCTIVE SURGERY

S Shivdas*, P Rathod, P RM, N Jain, P VR. Kidwai memorial Institute of Oncology, India

10.1136/ijgc-2020-IGCS.319

Introduction Intraperitoneal (IP) Chemotherapy and HIPEC have come to be accepted as standard options in advanced EOC, but are associated with morbidities and treatment delay. This study was done to evaluate the feasibility of administering single dose intraoperative normothermic IP carboplatin in advanced EOC after optimal primary or interval debulking surgery.

Methods In a Phase II non randomized prospective study from January 2015 to December 2019, patients of optimally cytoreduced advanced high grade serous ovarian cancer, were administered single dose intraoperative IP carboplatin at room temperature. The immediate (< 6 hours), early (6 – 48 hours) and late (48 hours – 21 days) perioperative complications were recorded, and analyzed.

Results Of 356 patients who underwent surgery for advanced EOC, 86 patients met the inclusion and exclusion criteria. 12 (14%) patients underwent PDS and 74 (86%) IDS. 13 (15.1%) patients underwent laparoscopic/robotic IDS. All patients tolerated IP carboplatin well with no or minimal adverse events. Three cases (3.5%) needed re-suturing for burst abdomen, three cases (3.5%) had paralytic ileus, one case underwent re-exploration for hemorrhage, and one patient died due to late sepsis. 84 (97.7%) patients received adjuvant IV chemotherapy on time.

Conclusion Single dose normothermic intraoperative IP carboplatin is a feasible procedure with no or minimal manageable morbidity. The procedure is user friendly combining the prognostic benefits of IP chemotherapy with assurance of early timely administration of chemotherapy in advanced EOC. Our study is hypothesis generating for future clinical trials comparing single dose NIPEC versus HIPEC in advanced EOC.

IGCS20_1396

370 THE IMPACTS OF NEOADJUVANT CHEMOTHERAPY AND OF CYTOREDUCTIVE SURGERY ON TEN-YEAR SURVIVAL FROM ADVANCED OVARIAN CANCER

¹S Kim*, ²J Kotsopoulos, ²P Sun, ¹M Bernardini, ¹S Laframboise, ¹S Ferguson, ³B Rosen, ²S Narod, ¹T May. ¹Department of Obstetrics and Gynecology, University of Toronto, Canada; ²Women's College Research Institute, Women's College Hospital, Canada; ³Beaumont Health System, USA

10.1136/ijgc-2020-IGCS.320

Objective To compare long-term survival outcomes for women with advanced ovarian cancer treated with chemotherapy, either before (neoadjuvant) or after surgery (primary cytoreductive) treated at a single tertiary cancer center.

Methods Retrospective hospital-based cohort study of 326 patients with stage IIIC or IV high-grade serous ovarian cancer who received neoadjuvant chemotherapy or primary cytoreductive surgery between 2001 and 2011. Clinical treatments were recorded and ten-year survival rates were measured.

Results A total of 183 women (56%) underwent primary cytoreductive surgery and 143 women (44%) received neoadjuvant chemotherapy. Women who had neoadjuvant chemotherapy were more likely to have no residual disease than those who underwent primary cytoreductive surgery (51.4% versus 41.5%) and they experienced inferior ten-year overall survival (9.1% versus 19.3%; $p < 0.0001$). Among those who had primary cytoreductive surgery, those with no residual disease had superior ten-year overall survival than those who had any residual disease (36.0% versus 7.2%).

Conclusion Among women with advanced ovarian cancer, those who have undergone primary cytoreductive surgery have better survival than those who received neoadjuvant chemotherapy. Neoadjuvant chemotherapy should be reserved for patients who are not candidates for primary cytoreductive surgery.

IGCS20_1397

371

RELATIVE CONDITIONAL SURVIVAL IN WOMEN WITH NEWLY-DIAGNOSED OVARIAN CANCER IN THE UNITED STATES: RESULTS FROM THE TEMPUS DATASET, 1982-2018

¹E Szamreta*, ¹M Monberg, ¹K Desai, ¹X Chen, ²M Othus. ¹Merck and Co., Inc., USA; ²Fred Hutchinson Cancer Research Center, USA

10.1136/ijgc-2020-IGCS.321

Objectives Prognosis in ovarian cancer is poor. Previous conditional survival (CS) studies have found outcomes improved based on each year survived since diagnosis. Our objective was to estimate CS and compare to previous studies (≤ 2010). **Methods** The Tempus EMR dataset includes patients from National Cancer Institute designated centers and community oncology centers across the U.S. This study included adult women with a primary diagnosis of ovarian, fallopian tube, or peritoneal cancer from 1982–2018; women treated with a poly-ADP ribose polymerase (PARP) inhibitor were excluded due to low numbers (final $n=3,370$). We calculated relative 5-

Abstract 371 Table 1

Relative conditional 5-year survival (OS)	At diagnosis	1 yr. since diagnosis	2 yrs. since diagnosis	3 yrs. since diagnosis	4 yrs. since diagnosis	5 yrs. since diagnosis
Current study (2020) (Tempus data, 1982-2018)						
All stages (n=3,206)	41.3%	35.7%	34.5%	35.8%	36.2%	39.0%
FIGO Stage I (n=131)	71.2%	71.3%	64.9%	63.0%	60.8%	60.6%
Stage II (n=130)	58.6%	59.6%	55.1%	55.1%	51.5%	46.5%
Stage III (n=1,315)	44.1%	36.5%	35.2%	34.7%	37.6%	39.3%
Stage IV (n=523)	26.0%	23.3%	19.7%	19.0%	15.3%	15.3%
Unknown stage (n=1,107)	39.2%	32.9%	32.1%	35.6%	34.2%	38.7%
Ries, et al. (2003) (SEER data, 1990-1999)						
All stages	53%	66%	76%	86%	--	--
AJCC Stage I	94%	--	--	--	--	--
Stage II	78%	--	--	--	--	--
Stage III	45%	--	--	--	--	--
Stage IV	19%	--	--	--	--	--
Unknown stage	49%	--	--	--	--	--
Choi, et al. (2008) (SEER data, 1988-2003)						
AJCC Stage I	90%	91%	93%	93%	94%	95%
Stage II	65%	71%	76%	79%	82%	85%
Stage III	34%	38%	44%	51%	57%	65%
Stage IV	17%	24%	30%	38%	47%	56%
Merrill, et al. (2010) (SEER data, 1990-2006)						
Local	92.7%	93.7%	94.3%	94.9%	95.3%	94.9%
Regional	67.6%	74.6%	79.1%	83.3%	86.5%	89.1%
Distant	29.3%	37.2%	44.2%	52.6%	60.3%	69.3%
Unknown	28.8%	51.9%	63.9%	71.6%	78.1%	85.1%